Cargando…
Normal Hematopoietic Stem Cells within the AML Bone Marrow Have a Distinct and Higher ALDH Activity Level than Co-Existing Leukemic Stem Cells
Persistence of leukemic stem cells (LSC) after chemotherapy is thought to be responsible for relapse and prevents the curative treatment of acute myeloid leukemia (AML) patients. LSC and normal hematopoietic stem cells (HSC) share many characteristics and co-exist in the bone marrow of AML patients....
Autores principales: | Schuurhuis, Gerrit J., Meel, Michael H., Wouters, Floris, Min, Lisa A., Terwijn, Monique, de Jonge, Nick A., Kelder, Angele, Snel, Alexander N., Zweegman, Sonja, Ossenkoppele, Gert J., Smit, Linda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823975/ https://www.ncbi.nlm.nih.gov/pubmed/24244383 http://dx.doi.org/10.1371/journal.pone.0078897 |
Ejemplares similares
-
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
por: Terwijn, Monique, et al.
Publicado: (2014) -
AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML
por: Hanekamp, Diana, et al.
Publicado: (2021) -
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
por: Cloos, Jacqueline, et al.
Publicado: (2018) -
Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia
por: Zeijlemaker, Wendelien, et al.
Publicado: (2019) -
MRD Tailored Therapy in AML: What We Have Learned So Far
por: Ngai, Lok Lam, et al.
Publicado: (2021)